The SNP at −592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development
Tóm tắt
Women with Human Papilloma Virus (HPV) persistence are characterized by high levels of IL-10 at cervix. We have determined whether polymorphisms of IL-10 gene promoter might be associated with increased risk of squamous intraepithelial cervical lesions (SICL) and whether exist significative differences of IL-10 mRNA expression at cervix and systemic and serum IL-10 protein between SICL cases and non-Cervical Lesions (NCL).
Peripheral blood samples from SICL (n = 204) and NCL (n = 166) were used to detect IL-10 promoter polymorphisms at loci -592A/C (rs1800872), -819C/T (rs1800871), -1082A/G (rs1800896), -1352A/G (rs1800893), by allelic discrimination and to evaluate serum IL-10 protein. Cervical epithelial scrapings from NCL and biopsies from SICLs were used for HPV-typing and to evaluate IL-10 mRNA expression level. The systemic and local IL-10 mRNA expression levels were measured by real time-PCR. Genotypic and allelic frequencies of the selected polymorphisms were analyzed by logistic regression, adjusting by age and HPV-genotype, to determine the association with SICL.
No significant differences were found between genotype frequencies at loci −819, -1082, and −1352. Individuals carrying at least one copy of risk allele A of polymorphism −592 had a two-fold increased risk of developing SICL [adjusted odds ratio (OR), 2.02 (95% CI, 1.26-3.25), p = 0.003], compared to NCL. The IL-10 mRNA expression and serum IL-10 protein, were significantly higher in SICL cases (p < 0.01), being higher in patients carrying the risk allele A.
The −592 polymorphism is associated with increased risk of SICL and can serve as a marker of genetic susceptibility to SICL among Mexican women. According to IL-10 levels found in SICL, IL-10 can be relevant factor for viral persistence and progression disease.
Từ khóa
Tài liệu tham khảo
Guzmán-Olea E, Bermúdez-Morales VH, Peralta-Zaragoza O, Torres-Poveda K, Madrid-Marina V: Molecular mechanisms and potential targets to blocking HPV-induced lesion development. J Oncol. 10.1155/2012/278312. Epub 2011. Article ID 278312, 11 pages
Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B: Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997, 89: 245-250. 10.1093/jnci/89.3.245.
Giannini SL, Al-Saleh W, Piron H, Jacobs N, Doyen J, Boniver J: Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol. 1998, 113: 183-189. 10.1046/j.1365-2249.1998.00639.x.
Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R: In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cancer cells. Viral Immunol. 2006, 19: 481-491. 10.1089/vim.2006.19.481.
de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH: Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer. 1999, 35: 490-497. 10.1016/S0959-8049(98)00371-2.
Bermúdez-Morales VH, Gutiérrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V: Correlation between IL-10 expression and human papillomavirus infection in cervical cancer. A mechanism for immune response escape. Cancer Investig. 2008, 26: 1037-1043. 10.1080/07357900802112693.
Díaz-Benítez CE, Navarro-Fuentes KR, Flores-Sosa JA, Juárez-Díaz J, Uribe-Salas FJ, Román-Basaure E: CD3ζ expression and T cell proliferation are inhibited by TGF-β1 and IL-10 in cervical cancer patients. J Clin Immunol. 2009, 29: 532-544. 10.1007/s10875-009-9279-7.
Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol. 1999, 11: 165-190.
Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993, 150: 353-360.
Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM: B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002, 3: 944-950.
de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Ait-Yahia S: The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998, 160: 1666-1676.
Thompson-Snipes L, Dahr V, Bond MW, Mosmann TR, Moore KW, Rennick DM: Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med. 1991, 173: 507-510. 10.1084/jem.173.2.507.
Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD: IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol. 1995, 154: 1280-1286.
Mocellin S, Marincola FM, Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005, 78: 1043-1051. 10.1189/jlb.0705358.
Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A: Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA. 1992, 89: 7708-7712. 10.1073/pnas.89.16.7708.
Venetsanakos E, Beckman I, Bradley J, Skinner JM: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997, 75: 1826-1830. 10.1038/bjc.1997.311.
Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer. 1995, 63: 366-371. 10.1002/ijc.2910630311.
Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 1995, 55: 3847-3853.
Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T: IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 1995, 155: 2240-2247.
Chen Q, Daniel V, Maher DW, Hersey P: Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994, 56: 755-760. 10.1002/ijc.2910560524.
Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997, 71: 630-637. 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin- 10 gene promoter. Eur J Immunogenet. 1997, 24: 1-8. 10.1111/j.1365-2370.1997.tb00001.x.
Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH: Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002, 184: 57-63. 10.1016/S0304-3835(02)00193-3.
Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV: Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001, 94: 792-794. 10.1002/ijc.1543.
Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG: Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005, 15: 282-290. 10.1111/j.1525-1438.2005.00433.x.
El-Sherif AM, Seth R, Tighe PJ, Jenkins D: Quantitative analysis of IL-10 and IFN-c mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol. 2001, 195: 179-185. 10.1002/path.929.
Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H: Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis. 1994, 70: 1077-1085.
Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res. 1991, 82: 524-531. 10.1111/j.1349-7006.1991.tb01882.x.
de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ: The use general primers GP5 and GP6 elongated at their 3′end with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995, 76: 1057-1062. 10.1099/0022-1317-76-4-1057.
Del Refugio González-Losa M, Laviada M, Terán MA, Puerto-Solís M, García-Carrancá A: Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. J Clin Virol. 2004, 29: 95-98. 10.1016/S1386-6532(03)00094-5.
Lizano M, De La Cruz-Hernández E, Carrillo-García A, García-Carrancá A, Ponce De León-Rosales S, Dueñas-González A: Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol. 2006, 102: 230-235. 10.1016/j.ygyno.2005.12.002.
Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T: Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol. 2004, 35: 1376-1384. 10.1016/j.humpath.2004.08.012.
Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L: Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med. 1998, 158: 1958-1962.
Steinke JW, Barekzi E, Hagman J, Borish L: Functional analysis of −571 IL-10 promoter polymorphism reveals a repressor element controlled by Sp1. J Immunol. 2004, 173: 3215-3222.
Peralta-Zaragoza O, Bermúdez-Morales VH, Gutiérrez-Xicotencatl L, Alcocer-González J, Recillas-Targa F, Madrid-Marina V: E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human TGFβ1 promoter throughout Sp1 recognition sequence. Viral Immunol. 2006, 19: 468-480. 10.1089/vim.2006.19.468.
Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE: Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol. 1997, 24: 2314-2317.
Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G: Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens. 1997, 49: 635-639. 10.1111/j.1399-0039.1997.tb02812.x.
Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnott P: IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol. 1998, 27: 142-145. 10.1080/030097498441029.
MacDonald TT: Gastrointestinal inflammation: inflammatory bowel disease in knockout mice. Curr Biol. 1994, 4: 261-263. 10.1016/S0960-9822(00)00060-9.
Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM: Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998, 92: 3943-3948.
Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ: Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA. 2000, 97: 14467-14472. 10.1073/pnas.97.26.14467.
Chatterjee A, Rathore A, Sivarama P, Yamamoto N, Dhole TN: Genetic Association of IL-10 Gene Promoter Polymorphism and HIV-1 Infection in North Indians. J Clin Immunol. 2009, 29 (1): 71-77. 10.1007/s10875-008-9220-5.
Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G: Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996, 104: 1-5. 10.1016/0304-3835(96)04213-9.
Chopra V, Dinh TV, Hannigan EV: Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest. 1998, 16: 152-159. 10.3109/07357909809050029.